MedTrace Logo

Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients

NCT04673591 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2022-02-08

No results posted yet for this study

Summary

The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.

Conditions

  • Allergy to House Dust Mite
  • Allergic Asthma

Interventions

DRUG

Tregalizumab

a monoclonal antibody designed for the treatment of allergic asthma indication

OTHER

Placebo

Matched Placebo

Sponsors & Collaborators

  • T-Balance Therapeutics GmbH

    lead INDUSTRY

Principal Investigators

  • Stefan Zielen, Prof. Dr. · Medaimun GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-09
Primary Completion
2022-01-12
Completion
2022-01-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673591 on ClinicalTrials.gov